1424348-39-9

Basic information

• Product Name: (15α,17β)-3-(benzyloxy)-N-ethyl-17-methoxyestra-1,3,5(10)-triene-15-carboxamide
• Synonyms: (15α,17β)-3-(benzyloxy)-N-ethyl-17-methoxyestra-1,3,5(10)-triene-15-carboxamide
• CAS NO: 1424348-39-9
• Molecular Weight: 447.618
• Mol File: 1424348-39-9.mol

Chemical Properties

• CAS DataBase Reference: (15α,17β)-3-(benzyloxy)-N-ethyl-17-methoxyestra-1,3,5(10)-triene-15-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (15α,17β)-3-(benzyloxy)-N-ethyl-17-methoxyestra-1,3,5(10)-triene-15-carboxamide(1424348-39-9)
• EPA Substance Registry System: (15α,17β)-3-(benzyloxy)-N-ethyl-17-methoxyestra-1,3,5(10)-triene-15-carboxamide(1424348-39-9)

Safety Data

• Hazardous Substances Data: 1424348-39-9(Hazardous Substances Data)

Upstream product

• 1424348-11-7 (15α,17β)-3-(benzyloxy)-17-methoxyestra-1,3,5(10)-triene-15-carboxylic acid 
• 1424348-13-9 methyl (15α,17β)-3-(benzyloxy)-17-methoxyestra-1,3,5(10)-triene-15-carboxylate 
• 557-66-4 ethanamine hydrochloride 
• 534572-70-8 (15α,17β)-3-(benzyloxy)-17-hydroxyestra-1,3,5(10)-triene-15-carboxylic acid 
• 138743-03-0 (14α)-3-benzyloxy-1,3,5(10),15-estratetraen-17-one 

Relevant articles and documents

Discovery of novel steroidal histamine H3 receptor antagonists/inverse agonists. Part 2. Versatile steroidal carboxamide derivatives

To further proceed with our previous work, novel steroid-based histamine H3 receptor antagonists were identified and characterized. Using an ‘amine-to-amide’ modification strategy at position 17, in vitro and in vivo potent monoamino steroid derivatives were found during the lead optimization. Usage of the non-basic amide moiety resulted in beneficial effects both in activity and selectivity. The 15α-carboxamido derivative 10 was not only highly active at human and rat H3 receptors, but also showed negligible activity at rat muscarinic receptors. Furthermore, it proved to be considerably stable in human and rat microsomes and showed significant in vivo potency in the pharmacodynamic rat dipsogenia test and in the water-labyrinth cognitive model. Based on all of these considerations, compound 10 was appointed to be a preclinical candidate.

HISTAMINE H3 ANTAGONIST STEROIDAL CARBOXAMIDES

The present invention relates to new histamine-3 (H3) receptor subtype preferring ligands of formula (I) (as defined in the claims) and/or geometric isomers and/or stereoisomers and/or diastereoisomers and/or salts and/or hydrates and/or solvates thereof. The invention further relates to pharmaceutical compositions comprising such compounds and the use of these compounds in methods for treating or preventing of conditions which require modulation of histamine-3 (H3) receptors. The invention also provides a method for manufacturing medicaments useful in the treatment or prevention of such conditions.